|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
|
IN2014DN10515A
(enExample)
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
TWI700293B
(zh)
|
2008-04-11 |
2020-08-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗體
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JP5959440B2
(ja)
|
2010-01-19 |
2016-08-02 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
病原体の検出および治療のための改変オプソニン
|
|
KR101712820B1
(ko)
*
|
2010-02-23 |
2017-03-22 |
사노피 |
항-알파2 인테그린 항체 및 그 용도
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
AU2011325833C1
(en)
*
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
KR102568454B1
(ko)
|
2010-11-30 |
2023-08-18 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
|
JP6147670B2
(ja)
*
|
2010-12-22 |
2017-06-14 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
改善された半減期を有する修飾された抗体
|
|
EP3604330A1
(en)
|
2011-02-25 |
2020-02-05 |
Chugai Seiyaku Kabushiki Kaisha |
Fcgammariib-specific fc antibody
|
|
US10654916B2
(en)
|
2011-04-21 |
2020-05-19 |
The Regents Of The University Of California, A California Corporation |
Compositions and methods for the treatment of neuromyelitis optica
|
|
EP2704744B1
(en)
|
2011-05-05 |
2019-04-24 |
Wellstat ImmunoTherapeutics, LLC |
Complement factor b analogs and their uses
|
|
BR112013031943B1
(pt)
|
2011-06-13 |
2021-10-13 |
Csl Limited |
Composição que compreende proteínas e anticorpos contra g-csfr
|
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
AU2012284097B2
(en)
|
2011-07-18 |
2017-08-03 |
President And Fellows Of Harvard College |
Engineered microbe-targeting molecules and uses thereof
|
|
FI2734552T3
(fi)
|
2011-07-22 |
2025-02-12 |
Csl Behring Gmbh |
Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö
|
|
EP2548892A1
(en)
|
2011-07-22 |
2013-01-23 |
CSL Behring GmbH |
Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
|
|
US10556949B2
(en)
|
2011-09-30 |
2020-02-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP2787078B1
(en)
|
2011-10-31 |
2019-05-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
BR112014013081A2
(pt)
|
2011-11-30 |
2020-10-20 |
Chugai Seiyaku Kabushiki Kaisha |
veículo contendo fármaco em célula para formação de um complexo imune
|
|
AU2012362217A1
(en)
*
|
2011-12-28 |
2014-07-24 |
Novelmed Therapeutics, Inc. |
Aglycosylated human antibody and fusion protein and uses thereof
|
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
|
JP6226752B2
(ja)
*
|
2012-02-09 |
2017-11-08 |
中外製薬株式会社 |
抗体のＦｃ領域改変体
|
|
MX382840B
(es)
|
2012-04-27 |
2025-03-13 |
Bioatla Llc |
Regiones de anticuerpo modificado y sus usos.
|
|
ES2718478T3
(es)
|
2012-06-08 |
2019-07-02 |
Sutro Biopharma Inc |
Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
|
EP2867251B1
(en)
*
|
2012-06-29 |
2019-08-21 |
Bristol-Myers Squibb Company |
Methods for reducing glycoprotein aggregation
|
|
US20140154253A1
(en)
*
|
2012-07-13 |
2014-06-05 |
Zymeworks Inc. |
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
|
WO2014055784A1
(en)
|
2012-10-03 |
2014-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
US10077298B2
(en)
|
2012-11-28 |
2018-09-18 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CA2899693C
(en)
*
|
2013-01-30 |
2023-03-14 |
Vib Vzw |
Novel chimeric polypeptides for screening and drug discovery purposes
|
|
TWI635098B
(zh)
*
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
FI2953971T3
(fi)
|
2013-02-07 |
2023-04-27 |
Csl Ltd |
Il-11r-sitojaproteiineja ja niiden käyttöjä
|
|
JP6636334B2
(ja)
|
2013-03-08 |
2020-01-29 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
遠隔虚血再灌流傷害の治療および予防
|
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
WO2014144325A1
(en)
|
2013-03-15 |
2014-09-18 |
President And Fellows Of Harvard College |
Methods and compositions for improving detection and/or capture of a target entity
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP2970422B1
(en)
*
|
2013-03-15 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
|
WO2014190040A1
(en)
|
2013-05-21 |
2014-11-27 |
President And Fellows Of Harvard College |
Engineered heme-binding compositions and uses thereof
|
|
CN110511279B
(zh)
|
2013-05-30 |
2024-03-29 |
基尼克萨制药有限公司 |
制瘤素m受体抗原结合蛋白
|
|
KR101895634B1
(ko)
*
|
2013-05-31 |
2018-09-05 |
한미약품 주식회사 |
변이된 힌지 영역을 포함하는 IgG4 Fc 단편
|
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
PT3074424T
(pt)
|
2013-11-27 |
2025-05-29 |
Zymeworks Bc Inc |
Construções de ligação a antigénio biespecíficas direcionadas a her2
|
|
EP3083658B1
(en)
|
2013-12-18 |
2019-05-08 |
President and Fellows of Harvard College |
Crp capture/detection of gram positive bacteria
|
|
CN107074957B
(zh)
|
2014-01-13 |
2021-05-07 |
希望之城公司 |
在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
|
|
US10487140B2
(en)
|
2014-01-14 |
2019-11-26 |
Integrated Biotherapeutics, Inc. |
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
|
|
TW201619188A
(zh)
*
|
2014-03-05 |
2016-06-01 |
優稀美生物醫藥公司 |
多聚體Ｆｃ蛋白質
|
|
JP6851199B2
(ja)
*
|
2014-03-05 |
2021-03-31 |
ユーシービー バイオファルマ エスアールエル |
多量体Ｆｃタンパク質
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
KR102497443B1
(ko)
|
2014-03-28 |
2023-02-08 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
ES2900898T3
(es)
*
|
2014-04-07 |
2022-03-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecíficos inmunoactivadores
|
|
NO2776305T3
(enExample)
*
|
2014-04-23 |
2018-01-27 |
|
|
|
SG10201913507SA
(en)
|
2014-05-02 |
2020-02-27 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
CA2947157A1
(en)
|
2014-05-13 |
2015-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
DK3107938T3
(da)
|
2014-05-28 |
2022-07-11 |
Zymeworks Inc |
Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
AU2015350075B2
(en)
|
2014-11-17 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using CD3xCD20 bispecific antibody
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
TWI656133B
(zh)
|
2014-12-19 |
2019-04-11 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
|
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
MA41459A
(fr)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
|
WO2016125495A1
(en)
*
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10556952B2
(en)
|
2015-03-30 |
2020-02-11 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to Fc gamma receptors
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
FI3325011T6
(fi)
|
2015-07-24 |
2023-05-11 |
|
Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
|
|
EP3763378A1
(en)
|
2015-08-06 |
2021-01-13 |
President and Fellows of Harvard College |
Improved microbe-binding molecules and uses thereof
|
|
JP2018527350A
(ja)
*
|
2015-09-01 |
2018-09-20 |
イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． |
血餅形成の予防及び／又は血栓症の治療のための分子構築物
|
|
TWI784917B
(zh)
|
2015-09-23 |
2022-11-21 |
美商再生元醫藥公司 |
最優化抗ｃｄ３雙特異性抗體及其用途
|
|
US20170096485A1
(en)
*
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
PT3359576T
(pt)
|
2015-10-08 |
2025-03-27 |
Zymeworks Bc Inc |
Constructos de polipeptídeo de ligação a antigénio compreendendo cadeias leves capa e lambda e usos dos mesmos
|
|
US10703786B2
(en)
|
2015-10-30 |
2020-07-07 |
The University Of Melbourne |
Methods and compositions for improving glucose metabolism
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
KR102802396B1
(ko)
|
2015-11-27 |
2025-05-07 |
씨에스엘 리미티드 |
Cd131 결합 단백질 및 이의 용도
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
CA3004288C
(en)
|
2015-12-28 |
2025-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
|
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
ES2972740T3
(es)
|
2016-03-02 |
2024-06-14 |
Momenta Pharmaceuticals Inc |
Procedimientos relacionados con construcciones de Fc modificadas genéticamente
|
|
TW202214700A
(zh)
|
2016-03-14 |
2022-04-16 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
|
PL3484514T3
(pl)
|
2016-05-23 |
2024-04-29 |
Momenta Pharmaceuticals, Inc. |
Kompozycje i sposoby związane z projektowanymi konstruktami Fc
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
|
MX2019000887A
(es)
*
|
2016-07-22 |
2019-09-04 |
Gliknik Inc |
Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc.
|
|
KR20250036943A
(ko)
|
2016-08-02 |
2025-03-14 |
비스테라, 인크. |
조작된 폴리펩티드 및 그의 용도
|
|
CN109689099B
(zh)
|
2016-08-05 |
2023-02-28 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
PE20240950A1
(es)
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
JP7519774B2
(ja)
|
2016-12-09 |
2024-07-22 |
グリックニック インコーポレイテッド |
多価ｆｃ化合物を用いる炎症性疾患の治療方法
|
|
BR112019013955A2
(pt)
|
2017-01-06 |
2020-02-11 |
Momenta Pharmaceuticals, Inc. |
Composições e métodos relacionados a construtos de fc manipulados
|
|
KR20230132603A
(ko)
|
2017-01-11 |
2023-09-15 |
브리스톨-마이어스 스큅 컴퍼니 |
Psgl-1 길항제 및 그의 용도
|
|
CA3054067A1
(en)
|
2017-03-14 |
2018-09-20 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
|
MA50435A
(fr)
*
|
2017-05-24 |
2020-09-02 |
Als Therapy Development Inst |
Anticorps anti-ligand anti-cd40 thérapeutiques
|
|
KR102905526B1
(ko)
|
2017-06-27 |
2025-12-30 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
|
EP3645044A4
(en)
|
2017-06-27 |
2021-04-28 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
|
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
|
KR20220031738A
(ko)
|
2017-06-27 |
2022-03-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019069229A1
(en)
|
2017-10-02 |
2019-04-11 |
Neuracle Science Co., Ltd. |
USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
ES2939461T3
(es)
|
2017-11-29 |
2023-04-24 |
Csl Ltd |
Método para tratar o prevenir la lesión por isquemia-reperfusión
|
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
|
WO2019178645A1
(en)
|
2018-03-23 |
2019-09-26 |
Csl Limited |
Method of treating asthma
|
|
GB201814562D0
(en)
|
2018-09-07 |
2018-10-24 |
Hummingbird Bioscience Pte Ltd |
Vista antigen-binding molecules
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
KR20200118913A
(ko)
|
2018-04-24 |
2020-10-16 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
|
CN112074605B
(zh)
|
2018-05-08 |
2024-11-22 |
纽洛可科学有限公司 |
抗fam19a5抗体的腺相关病毒（aav）递送
|
|
CA3098805A1
(en)
|
2018-05-10 |
2019-11-14 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
KR102848349B1
(ko)
|
2018-06-04 |
2025-08-21 |
바이오젠 엠에이 인코포레이티드 |
감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
|
|
EP3841124A4
(en)
|
2018-06-29 |
2022-03-23 |
ApitBio, Inc. |
ANTI-L1CAM ANTIBODIES AND USES THEREOF
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
AU2019309472A1
(en)
*
|
2018-07-24 |
2021-03-18 |
Good T Cells, Inc. |
Composition for preventing or treating immune-related diseases
|
|
IL280875B2
(en)
|
2018-08-31 |
2024-12-01 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
MX2021003765A
(es)
|
2018-10-03 |
2021-07-15 |
Xencor Inc |
Proteínas il-12 de fusión a fc heterodimérico.
|
|
EP3867272A4
(en)
|
2018-10-16 |
2022-08-03 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES
|
|
KR20210111242A
(ko)
|
2018-10-29 |
2021-09-10 |
바이오젠 엠에이 인코포레이티드 |
혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체
|
|
JP7315256B2
(ja)
|
2018-12-05 |
2023-07-26 |
ヘッジホッグ，インコーポレイテッド |
エンドセリン受容体ａ活性調節抗体
|
|
WO2020118042A1
(en)
|
2018-12-05 |
2020-06-11 |
Jacobs Wagner Christine |
Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
|
|
KR102757347B1
(ko)
|
2018-12-27 |
2025-01-23 |
주식회사 뉴라클사이언스 |
죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
|
|
CN117964756A
(zh)
|
2019-01-02 |
2024-05-03 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
EA202192400A1
(ru)
|
2019-04-08 |
2022-01-25 |
Биоген Ма Инк. |
Антитела против интегрина и их применение
|
|
CN114174330B
(zh)
|
2019-05-28 |
2025-01-17 |
总医院公司 |
Apoe抗体、融合蛋白及其用途
|
|
JP7775080B2
(ja)
*
|
2019-07-01 |
2025-11-25 |
トニックス ファーマ リミテッド |
抗ｃｄ１５４抗体およびその使用
|
|
WO2021006328A1
(en)
|
2019-07-10 |
2021-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
JP7807372B2
(ja)
|
2019-12-20 |
2026-01-27 |
ハドソン インスティチュート オブ メディカル リサーチ |
Ｃｘｃｌ１０結合タンパク質及びその使用
|
|
CN111257445B
(zh)
*
|
2020-01-22 |
2022-09-09 |
上海交通大学医学院附属仁济医院 |
用于sle孕妇病情监测及其胎儿结局预测的产品及方法
|
|
EP4130047A4
(en)
*
|
2020-02-27 |
2024-07-31 |
Huahui Health Ltd. |
SOLUBLE ACE2 AND FUSION PROTEIN AND THEIR USES
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
JP7766049B2
(ja)
*
|
2020-05-20 |
2025-11-07 |
ザイムワークス ビーシー インコーポレイテッド |
安定性強化変異を含む免疫グロブリンＦｃ領域バリアント
|
|
LT4200018T
(lt)
|
2020-08-18 |
2025-03-25 |
Cephalon Llc |
Anti-par-2 antikūnai ir jų panaudojimo būdas
|
|
JP7773528B2
(ja)
|
2020-08-19 |
2025-11-19 |
ゼンコア インコーポレイテッド |
抗ｃｄ２８組成物
|
|
EP4284936A1
(en)
|
2021-01-26 |
2023-12-06 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
US20230016731A1
(en)
*
|
2021-05-21 |
2023-01-19 |
The Regents Of The University Of California |
Affinity purification sequencing
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
TW202322850A
(zh)
*
|
2021-08-05 |
2023-06-16 |
美商美國禮來大藥廠 |
抗體最佳化
|
|
IL312221A
(en)
|
2021-10-20 |
2024-06-01 |
Synthekine Inc |
Heterodimeric fc cytokines and uses thereof
|
|
EP4460522A1
(en)
|
2022-01-09 |
2024-11-13 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same
|
|
WO2024054993A1
(en)
|
2022-09-09 |
2024-03-14 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-ctla4 antibodies and methods of using the same
|
|
WO2025007195A1
(en)
|
2023-07-05 |
2025-01-09 |
CSL Innovation Pty Ltd |
Methods of treating or preventing a complication of sickle cell disease
|
|
AU2024287813A1
(en)
|
2023-07-07 |
2026-01-22 |
Kriya Therapeutics, Inc. |
Periocular delivery of aav vectors for treating ophthalmic pathologies
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|
|
WO2026039779A1
(en)
|
2024-08-15 |
2026-02-19 |
Yale University |
Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
|